Navigation Links
Venaxis Announces Pricing of Offering of Common Stock and Warrants
Date:5/23/2013

CASTLE ROCK, Colo., May 23, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq:   APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and related warrants to purchase 3,500,000 shares of its common stock at an exercise price of $1.36 per share at a combined public offering price of $1.25 per share and related warrant.  Venaxis has also granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares and related warrants to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any.  The shares of common stock and warrants are immediately separable and will be issued separately in the offering. The offering is expected to close on May 30, 2013, subject to customary closing conditions.  All of the shares and warrants in the offering are being sold by Venaxis.

Venaxis expects to receive net proceeds from the offering of approximately $11.1 million, after deducting estimated underwriting discounts and commissions and offering expenses. Venaxis intends to use the net proceeds from the offering primarily for general corporate purposes, including funding for further clinical development, seeking FDA clearance for APPY1, and for initial commercialization of APPY1 in the U.S. and the E.U. 

Piper Jaffray & Co. is acting as sole manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on May 23, 2013.  The offering is being made only by means of a prospectus.  A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
2. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
3. PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits
4. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
5. Emerson Resources Announces CEO Retirement and Appointment of Successor
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
8. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
9. SoundConnect Announces Microsoft Lync Release in Canada
10. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
11. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Biomarkers Inc., a,leading developer of protein biomarker ... the launch of the AVANTRA(TM) biomarker,workstation along ... The system,s ease-of-use enables users to generate ... project productivity., The AVANTRA(TM) biomarker workstation ...
... plc,(NASDAQ: AMRND ) today announced that, at a ... 10 reverse split of each of its Ordinary,Shares. The ... business,yesterday, January 17, 2008., Thomas Lynch, Amarin Chairman ... report that over 95% of the votes cast by ...
... Ltd.,(Bloomberg: BIG SP, Company or Biosensors), today announced ... approval for its,BioMatrix(R) drug-eluting stent system, enabling commercialization ... countries in Asia and Latin America,that recognize the ... by the Company, consists of a unique drug-eluting,stent ...
Cached Biology Technology:Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers 2Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 2Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 3Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 4Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 5Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 6Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 7Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 8Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 9Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... May 30, 2011 Reportlinker.com announces that ... in its catalogue: Enzymes ... http://www.reportlinker.com/p0535955/Enzymes-in-Drug-Manufacturing.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biocatalysis in pharmaceutical ... enzyme and genomics technologies that are increasing ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
... drugs to combat or cure human disease often involves a ... clearly into a living mouse,s innards has real value. ... interior of laboratory mice, the view becomes so murky several ... divining the future from the rodent,s entrails than they do ...
Cached Biology News:Reportlinker Adds Enzymes in Drug Manufacturing 2Reportlinker Adds Enzymes in Drug Manufacturing 3Reportlinker Adds Enzymes in Drug Manufacturing 4Reportlinker Adds Enzymes in Drug Manufacturing 5Reportlinker Adds Enzymes in Drug Manufacturing 6Novel pathway regulating angiogenesis may fight retinal disease, cancers 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 3
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
...
Request Info...
Request Info...
Biology Products: